Pancreatic cancer protein biomarker detection kit and detection system

Abstract

The invention provides a pancreatic cancer protein biomarker detection kit including a CRP monoclonal antibody, an ICAM-1 monoclonal antibody, an OPG monoclonal antibody, a CA19-9 monoclonal antibody, and an enzyme-labelled secondary antibody for forming double antibody sandwich. The invention also provides a pancreatic cancer detection system comprising the detection kit. According to a detection chip and the detection kit, four pancreatic cancer protein biomarkers of CRP, ICAM-1, OPG and CA19-9 obtained through screening by means of 'subtraction method' are subjected to immunization to respectively prepare the specific CRP monoclonal antibody,the specific ICAM-1 monoclonal antibody, the specific OPG monoclonal antibody and the specific CA19-9 monoclonal antibody to be used as the basis, and the enzyme-labelled secondary antibody with double antibody sandwich is combined, and through antigen-antibody specific combination and combination of the enzyme-labelled secondary antibody with double antibody sandwich, biomarking proteins are detected, and higher accuracy and specificity are achieved.

Description

technical field [0001] The invention belongs to the technical field of biological detection, and in particular relates to a detection kit and a detection system for pancreatic cancer protein biomarkers. Background technique [0002] Pancreatic cancer is a highly malignant tumor of the digestive tract that is difficult to diagnose and treat. About 90% of them are ductal adenocarcinomas originating from the ductal epithelium. Usually after the onset of patients, the 5-year survival rate is <1%, which is one of the malignant tumors with the worst prognosis. [0003] An important reason for the low prognosis and survival rate of pancreatic cancer is that pancreatic cancer has no symptoms in the early stage, and it is difficult to be detected in the latent period or early stage of pancreatic cancer, thus delaying the best treatment time. It is mainly difficult to be detected because there are no symptoms in the early stage of the disease, and the most accurate detection marke...

AI Technical Summary

Problems solved by technology

[0003] An important reason for the low prognosis and survival rate of pancreatic cancer is that pancreatic cancer has no symptoms in the early stage, and it is difficult to be detected in the latent period or early stage of pancreatic cancer, thus delaying the best treatment time

It is mainly difficult to be detected because there are no symptoms in the early stage of the disease, and the most accurate detection markers currently available for pancreatic cancer, CA19-9, CEA, and CA242, have a certain positive rate when tested, and do not high specificity

According to statistical data, the sensitivity of using the above markers in the detection of pancreatic cancer during the gestation period (before canceration) is low. For example, 1 year before the onset, the sensitivity is 68%, and two years before the onset, the sensitivity is 53%.

However, using other conventional clinical techniques such as B-ultrasound, CT, MRI, ERCP, PTCD, angiography, laparoscopy, etc., when the cancer is found, it is already in the middle and late stage of the cancer, which greatly delays the diagnosis and treatment.

Images